149 related articles for article (PubMed ID: 10451039)
1. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
Sega R
Blood Press; 1999; 8(2):114-21. PubMed ID: 10451039
[TBL] [Abstract][Full Text] [Related]
2. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial.
Ruilope L; Jäger B; Prichard B
Blood Press; 2001; 10(4):223-9. PubMed ID: 11800061
[TBL] [Abstract][Full Text] [Related]
3. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
Punzi HA; Punzi CF
J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
[TBL] [Abstract][Full Text] [Related]
4. Effect of eprosartan and enalapril in the treatment of black hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Levine B
Curr Med Res Opin; 1999; 15(1):25-32. PubMed ID: 10216808
[TBL] [Abstract][Full Text] [Related]
5. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Argenziano L; Trimarco B
Curr Med Res Opin; 1999; 15(1):9-14. PubMed ID: 10216806
[TBL] [Abstract][Full Text] [Related]
6. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Gavras I; Gavras H
Curr Med Res Opin; 1999; 15(1):15-24. PubMed ID: 10216807
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
Hedner T; Himmelmann A
J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
[TBL] [Abstract][Full Text] [Related]
8. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group.
Gradman AH; Gray J; Maggiacomo F; Punzi H; White WB
Clin Ther; 1999 Mar; 21(3):442-53. PubMed ID: 10321414
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension.
Sachse A; Verboom CN; Jäger B
J Hum Hypertens; 2002 Mar; 16(3):169-76. PubMed ID: 11896506
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.
Elliott WJ
J Hum Hypertens; 1999 Jun; 13(6):413-7. PubMed ID: 10408592
[TBL] [Abstract][Full Text] [Related]
12. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
13. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
14. Eprosartan mesylate effectively reduces systolic and diastolic blood pressure in a Canadian primary care setting.
Conter HS; McKay DW; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():6C-10C. PubMed ID: 16807617
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term eprosartan versus enalapril antihypertensive therapy on left ventricular mass and coronary flow reserve in stage I-II hypertension. Eprosartan Study Group.
Diamond JA; Gharavi A; Roychoudhury D; Machac J; Henzlova MJ; Travis A; Phillips RA
Curr Med Res Opin; 1999; 15(1):1-8. PubMed ID: 10216805
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of eprosartan in combination with hydrochlorothiazide.
Böhm M; Sachse A
Drug Saf; 2002; 25(8):599-611. PubMed ID: 12113644
[TBL] [Abstract][Full Text] [Related]
17. Comparison of quality of life and cough on eprosartan and enalapril in people with moderate hypertension.
Breeze E; Rake EC; Donoghue MD; Fletcher AE
J Hum Hypertens; 2001 Dec; 15(12):857-62. PubMed ID: 11773988
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
Rake EC; Breeze E; Fletcher AE
J Hum Hypertens; 2001 Dec; 15(12):863-7. PubMed ID: 11773989
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.
Agrawal R; Marx A; Haller H
J Hypertens; 2006 Jan; 24(1):185-92. PubMed ID: 16331117
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
Teitelbaum I; Chilvers M; Reiz RJ
Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
